Mayflower Financial Advisors’s NovoCure NVCR Stock Holding History

Mayflower Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,518	Closed	-$212K	–	365
2023 Q1	$212K	Buy	3,518 +5	+0.1%	+$400	0.03%	320
2022 Q4	$258K	Sell	3,513 -7	-0.2%	-$527	0.04%	287
2022 Q3	$267K	Buy	3,520 +4	+0.1%	+$312	0.04%	266
2022 Q2	$244K	Buy	3,516 +7	+0.2%	+$527	0.04%	288
2022 Q1	$291K	Hold	3,509	–	–	0.04%	275
2021 Q4	$263K	Buy	3,509 +2	+0.1%	+$201	0.03%	285
2021 Q3	$412K	Hold	3,507	–	–	0.06%	216
2021 Q2	$778K	Hold	3,507	–	–	0.11%	129
2021 Q1	$464K	Hold	3,507	–	–	0.07%	171
2020 Q4	$607K	Buy	+3,507	New	+$480K	0.1%	137

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Mayflower Financial Advisors's NVCR Position: Q2 2023 in Review

Mayflower Financial Advisors sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 3,518 shares — an estimated $212K sold.

Mayflower Financial Advisors first reported a position in NVCR in Q4 2020 and held it in 10 quarters. The position peaked at $778K in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Mayflower Financial Advisors reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Mayflower Financial Advisors sold 3,518 NovoCure shares in Q2 2023, an estimated $212K.
Mayflower Financial Advisors first reported a position in NovoCure in Q4 2020 and held it in 10 quarters.
Mayflower Financial Advisors's NovoCure position peaked at $778K in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Mayflower Financial Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.